About BeiGene Ltd.

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.

At the moment the company generates 430M USD in revenues.

On its last earning announcement, the company reported a loss of -13.91$ per share.

The book value per share is 20.93$

BeiGene Ltd. website


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
430M -124.20% -853M -198.30% -829M -13.91 - - 60M 20.93 -677M -207M -884M